|
|
Millendo Therapeutics, a University of Michigan startup company, announced today that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
|
|
|
|
|
|
|
|
|
|